Leukemia drugs fall into four main groups: conventional chemotherapy, targeted drugs that block a specific abnormality in the leukemia cell, immunotherapies that direct the immune system against leukemia, and cellular therapies such as CAR-T cells. The biggest advances of recent decades have come from matching drugs to the genetic features of each leukemia, which has made several once-deadly subtypes manageable, and some curable.
This guide explains how each drug class works, which leukemias it is used for, what side effects to expect, and how doctors decide on a regimen. For the wider picture of the disease, see our leukemia guide.
What Leukemia Is and Why Drug Choice Varies
Leukemia is a cancer that starts in the bone marrow, the spongy tissue inside bones where blood cells are made. Our explainer on the composition and function of bone marrow describes that factory in detail. In leukemia, one early cell acquires genetic changes and produces large numbers of abnormal white blood cells that crowd out healthy ones.
There are four broad types: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). Each behaves differently and responds to different drugs, so the first step in treatment is always an accurate diagnosis.
Symptoms That Lead to Diagnosis
The signs and symptoms of leukemia mostly come from bone marrow failure: fatigue and breathlessness from anemia, infections from too few normal white cells, and bruising or bleeding from low platelets. Fever, night sweats, swollen lymph nodes, and an enlarged spleen are also common.
How Doctors Choose Leukemia Drugs
Treatment decisions rest on several tests. A complete blood count shows abnormal cell numbers and blasts (immature cells). Bone marrow aspiration and biopsy confirms the diagnosis and the type of leukemia.
Flow cytometry identifies the surface markers on leukemic cells, which matters for antibody drugs. Cytogenetics, FISH (fluorescent in situ hybridization), PCR, and gene sequencing look for chromosomal translocations and mutations. Many modern drugs are only used when a specific target, such as the BCR-ABL1 fusion or an FLT3 mutation, is present. Age, fitness, kidney and heart function, and patient preferences shape the final plan.
Major Classes of Leukemia Drugs
| Drug class | How it works | Examples | Main uses |
|---|---|---|---|
| Antimetabolites | Disrupt DNA building blocks in dividing cells | Cytarabine, methotrexate, 6-mercaptopurine, fludarabine | AML, ALL |
| Anthracyclines | Damage DNA and block its repair | Daunorubicin, idarubicin, doxorubicin | AML, ALL |
| Tyrosine kinase inhibitors | Block the overactive BCR-ABL1 signal | Imatinib, dasatinib, nilotinib, bosutinib, ponatinib | CML, Philadelphia-positive ALL |
| BTK inhibitors | Block B-cell receptor signaling | Ibrutinib, acalabrutinib, zanubrutinib | CLL |
| BCL-2 inhibitors | Remove a survival brake, triggering cell death | Venetoclax | CLL, AML in older or unfit adults |
| Mutation-directed drugs | Target FLT3 or IDH1/IDH2 mutations | Midostaurin, gilteritinib, ivosidenib, enasidenib | AML with those mutations |
| Hypomethylating agents | Reactivate silenced genes | Azacitidine, decitabine | AML in older adults |
| Antibodies and bispecifics | Mark leukemic cells for immune attack | Rituximab, obinutuzumab, blinatumomab, inotuzumab ozogamicin | CLL, B-cell ALL |
| CAR-T cell therapy | Engineered patient T cells that attack the leukemia | Tisagenlecleucel, brexucabtagene autoleucel | Relapsed or refractory B-cell ALL |
Chemotherapy: Still the Backbone
Chemotherapy kills rapidly dividing cells. In AML, the classic intensive induction pairs cytarabine with an anthracycline such as daunorubicin, often called “7+3” for the days each drug is given. ALL uses multi-drug regimens over two to three years, including steroids, vincristine, asparaginase, and maintenance with oral 6-mercaptopurine and methotrexate.
Because chemotherapy also hits healthy fast-growing cells, it causes low blood counts, hair loss, mouth sores, and nausea. Treatment is often given in phases: induction to achieve remission, consolidation to deepen it, and in ALL, maintenance.
Targeted Therapy: Precision Against Drivers
Imatinib transformed CML. A disease that once required transplant for any chance of long-term survival became, for most patients, a chronic condition controlled with a daily tablet. Newer TKIs work against mutations that cause resistance to imatinib.
In CLL, oral BTK inhibitors and venetoclax-based combinations have largely replaced chemotherapy for many patients. Some venetoclax regimens are given for a fixed period, then stopped. In AML, venetoclax combined with azacitidine has opened effective treatment to older adults who cannot tolerate intensive chemotherapy.
Immunotherapy and CAR-T Cells
Blinatumomab is a bispecific antibody that physically links a patient’s T cells to CD19 on B-cell leukemia cells. Inotuzumab ozogamicin carries a toxin directly into cells bearing CD22. CAR-T therapy takes a patient’s own T cells, genetically engineers them to recognize CD19, and infuses them back. These treatments are especially important in relapsed or refractory B-cell ALL.
Side Effects and Supportive Care
Every leukemia drug has trade-offs. Knowing the typical problems helps patients report them early.
- Infections: low neutrophil counts make fever a medical emergency during chemotherapy.
- Tumor lysis syndrome: rapid breakdown of leukemic cells can strain the kidneys; hydration and preventive drugs lower the risk, especially when starting venetoclax.
- Heart effects: anthracyclines have a lifetime dose limit, and some TKIs and BTK inhibitors affect heart rhythm or blood pressure.
- Cytokine release syndrome and neurotoxicity: expected with CAR-T cells and blinatumomab, and closely monitored.
- Bleeding and anemia: managed with transfusions of platelets and red cells as needed.
Supportive care, including antibiotics, antifungals, antiviral prophylaxis, anti-nausea drugs, and nutrition support, is as much a part of treatment as the leukemia drugs themselves.
Stem Cell Transplant and Where It Fits
An allogeneic stem cell transplant replaces the patient’s marrow with healthy donor cells. It is not a drug, but it depends on high-dose drugs to prepare the marrow and immunosuppressants afterward. The donor immune system also attacks remaining leukemic cells, known as the graft-versus-leukemia effect.
Transplant is usually considered for higher-risk AML and ALL once remission is achieved. Our overview of leukemia treatment from diagnosis to advanced strategies explains how it fits into the full care pathway.
Key Takeaways
- Leukemia drugs include chemotherapy, targeted drugs, antibodies, and cellular therapies, often used in combination.
- Genetic and marker testing now decides which drugs a patient receives.
- Targeted drugs such as TKIs, BTK inhibitors, and venetoclax have changed outcomes in CML, CLL, and AML in older adults.
- Side effects are real but manageable with close monitoring and supportive care.
Frequently Asked Questions
What is the most common drug used for leukemia?
There is no single drug for all leukemias. Cytarabine is central to AML treatment, multi-drug chemotherapy is standard for ALL, TKIs such as imatinib are first-line in CML, and BTK inhibitors or venetoclax combinations are widely used in CLL.
Can leukemia be treated with pills alone?
For some types, yes. CML is usually controlled with a daily oral TKI, and many CLL patients take oral targeted drugs. Acute leukemias generally still need intravenous treatment, at least initially.
Are targeted drugs better than chemotherapy?
They are better when the target is present and the drug is proven for that leukemia. They are not a universal replacement; in many acute leukemias, targeted drugs are added to chemotherapy rather than used instead of it.
How long do people take leukemia drugs?
It varies widely. AML intensive treatment lasts months, ALL treatment runs two to three years, and CML TKIs are often taken long-term, though some patients with deep, sustained responses can try stopping under close monitoring.
